Dr Reddys Laboratories is trading higher by 1% at Rs 1,969 after the pharmaceutical major said that it has launched Desloratadine ODT (Orally Disintegrating Tablets) in the US market on January 24, 2013.
“Dr Reddys ANDA for Desloratadine ODT, a bioequivalent generic version of Clarinex® Reditabs®, is approved by the United States Food and Drug Administration (USFDA),” the company said in a statement.
Dr. Reddy's Desloratadine ODT 2.5 mg & 5 mg are available in unit dose packages of 30 (5x6), it added.
Clarinex® Reditabs® brand had US sales of approximately $5.3 million for the most recent twelve months ending November 2012 according to IMS Health.
The stock opened at Rs 1,936 and touched a record high of Rs 1,970 on NSE. A combined 192,206 shares have changed hands on the counter so far on both the exchanges.